CO2019007298A2 - Inhibidores de tgfβ1 isoforma-específicos contexto-permisivos y uso de los mismos - Google Patents
Inhibidores de tgfβ1 isoforma-específicos contexto-permisivos y uso de los mismosInfo
- Publication number
- CO2019007298A2 CO2019007298A2 CONC2019/0007298A CO2019007298A CO2019007298A2 CO 2019007298 A2 CO2019007298 A2 CO 2019007298A2 CO 2019007298 A CO2019007298 A CO 2019007298A CO 2019007298 A2 CO2019007298 A2 CO 2019007298A2
- Authority
- CO
- Colombia
- Prior art keywords
- isoform
- context
- inhibitors
- permissive
- tgfβ1
- Prior art date
Links
- 102000001708 Protein Isoforms Human genes 0.000 title abstract 2
- 108010029485 Protein Isoforms Proteins 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 230000003831 deregulation Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
- G01N2333/495—Transforming growth factor [TGF]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
Abstract
En el presente documento se describe el uso terapéutico de inhibidores de TGFβ1 isoforma-específicos, contexto-permisivos, en el tratamiento de enfermedades que implican la desregulación de TGFβ1.
Applications Claiming Priority (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762443615P | 2017-01-06 | 2017-01-06 | |
US201762452866P | 2017-01-31 | 2017-01-31 | |
US201762514417P | 2017-06-02 | 2017-06-02 | |
US201762529616P | 2017-07-07 | 2017-07-07 | |
US201762549767P | 2017-08-24 | 2017-08-24 | |
US201762558311P | 2017-09-13 | 2017-09-13 | |
US201762585227P | 2017-11-13 | 2017-11-13 | |
US201762587964P | 2017-11-17 | 2017-11-17 | |
US201762588626P | 2017-11-20 | 2017-11-20 | |
PCT/US2018/012601 WO2018129329A1 (en) | 2017-01-06 | 2018-01-05 | ISOFORM-SPECIFIC, CONTEXT-PERMISSIVE TGFβ1 INHIBITORS AND USE THEREOF |
Publications (1)
Publication Number | Publication Date |
---|---|
CO2019007298A2 true CO2019007298A2 (es) | 2019-07-31 |
Family
ID=61198888
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CONC2019/0007298A CO2019007298A2 (es) | 2017-01-06 | 2019-07-08 | Inhibidores de tgfβ1 isoforma-específicos contexto-permisivos y uso de los mismos |
Country Status (17)
Country | Link |
---|---|
US (3) | US20180207267A1 (es) |
EP (1) | EP3551658A1 (es) |
JP (2) | JP7157744B2 (es) |
KR (2) | KR20240137126A (es) |
CN (2) | CN117398457A (es) |
AU (1) | AU2018205231A1 (es) |
BR (1) | BR112019013908A2 (es) |
CA (1) | CA3049005A1 (es) |
CL (1) | CL2019001874A1 (es) |
CO (1) | CO2019007298A2 (es) |
CR (1) | CR20190350A (es) |
DO (1) | DOP2019000180A (es) |
IL (2) | IL267790A (es) |
MX (1) | MX2019008197A (es) |
PE (1) | PE20191661A1 (es) |
PH (1) | PH12019501575A1 (es) |
WO (1) | WO2018129329A1 (es) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3055555A1 (en) | 2016-03-11 | 2017-09-14 | Scholar Rock, Inc. | Tgf.beta.1-binding immunoglobulins and use thereof |
EP3551658A1 (en) * | 2017-01-06 | 2019-10-16 | Scholar Rock, Inc. | Isoform-specific, context-permissive tgf 1 inhibitors and use thereof |
US20200231682A1 (en) | 2017-07-28 | 2020-07-23 | Scholar Rock, Inc. | Ltbp complex-specific inhibitors of tgf-beta 1 and uses thereof |
US11230601B2 (en) | 2017-10-10 | 2022-01-25 | Tilos Therapeutics, Inc. | Methods of using anti-lap antibodies |
LT3677278T (lt) | 2018-07-11 | 2022-01-10 | Scholar Rock, Inc. | Izoformoms selektyvūs tgfbeta1 inhibitoriai ir jų panaudojimas |
TW202019957A (zh) | 2018-07-11 | 2020-06-01 | 美商供石公司 | TGFβ1抑制劑及其用途 |
CA3105988A1 (en) | 2018-07-11 | 2020-01-16 | Abhishek Datta | High-affinity, isoform-selective tgf.beta.1 inhibitors and use thereof |
TW202035445A (zh) | 2018-10-10 | 2020-10-01 | 美商帝洛斯療法股份有限公司 | 抗lap抗體變異體及其用途 |
MX2021009175A (es) * | 2019-01-30 | 2021-09-14 | Scholar Rock Inc | Inhibidores especificos del complejo de ltbp de tgf? y usos de los mismos. |
SG11202110338XA (en) * | 2019-03-27 | 2021-10-28 | Singapore Health Serv Pte Ltd | Biomarker with therapeutic implications for peritoneal carcinomatosis |
US20220160751A1 (en) * | 2019-04-02 | 2022-05-26 | Yale University | Methods of treatment of diseases and disorders associated with increased tet level, increased h19 level, increased level of tgf signaling, or any combination thereof |
AR119594A1 (es) | 2019-08-09 | 2021-12-29 | Gilead Sciences Inc | Derivados de tienopirimidina como inhibidores acc y usos de los mismos |
KR102376605B1 (ko) | 2019-08-28 | 2022-03-21 | 추가이 세이야쿠 가부시키가이샤 | 종교차성 항잠재형 TGF-β1 항체 및 사용 방법 |
US11548871B2 (en) | 2019-11-15 | 2023-01-10 | Gilead Sciences, Inc. | Triazole carbamate pyridyl sulfonamides as LPA receptor antagonists and uses thereof |
EP4087659A2 (en) | 2020-01-11 | 2022-11-16 | Scholar Rock, Inc. | Tgf-beta inhibitors and use thereof |
CN115190812A (zh) | 2020-01-11 | 2022-10-14 | 供石公司 | TGFβ抑制剂及其用途 |
WO2021195485A1 (en) * | 2020-03-27 | 2021-09-30 | Vanderbilt University | Human monoclonal antibodies to severe acute respiratory syndrome coronavirus 2 (sars-cov-2) |
CA3177030A1 (en) | 2020-04-27 | 2021-11-04 | Aaron Sato | Variant nucleic acid libraries for coronavirus |
AU2021282986B2 (en) | 2020-06-03 | 2024-03-07 | Gilead Sciences, Inc. | LPA receptor antagonists and uses thereof |
TWI838626B (zh) | 2020-06-03 | 2024-04-11 | 美商基利科學股份有限公司 | Lpa受體拮抗劑及其用途 |
CN114957476A (zh) * | 2021-02-23 | 2022-08-30 | 复旦大学 | 一种半胱氨酸工程化的结合人5t4的全人源纳米抗体 |
WO2022204581A2 (en) | 2021-03-26 | 2022-09-29 | Scholar Rock, Inc. | Tgf-beta inhibitors and use thereof |
CA3218917A1 (en) | 2021-05-11 | 2022-11-17 | Gilead Sciences, Inc. | Lpa receptor antagonists and uses thereof |
CN117295724A (zh) | 2021-05-13 | 2023-12-26 | 吉利德科学公司 | Lpa受体拮抗剂及其用途 |
WO2022256723A2 (en) | 2021-06-03 | 2022-12-08 | Scholar Rock, Inc. | Tgf-beta inhibitors and therapeutic use thereof |
EP4370148A1 (en) | 2021-07-14 | 2024-05-22 | Scholar Rock, Inc. | Ltbp complex-specific inhibitors of tgf beta1 and uses thereof |
AU2022405082A1 (en) | 2021-12-08 | 2024-07-11 | Gilead Sciences, Inc. | Lpa receptor antagonists and uses thereof |
AU2022417491A1 (en) | 2021-12-22 | 2024-05-23 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
CA3239528A1 (en) | 2021-12-22 | 2023-06-29 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
EP4245756B1 (en) | 2022-03-17 | 2024-10-09 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
KR102628959B1 (ko) | 2022-03-22 | 2024-01-24 | 오토텔릭바이오 주식회사 | 티아졸 유도체 화합물 및 이의 용도 |
WO2024137852A1 (en) | 2022-12-22 | 2024-06-27 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
WO2024187051A1 (en) | 2023-03-07 | 2024-09-12 | Scholar Rock, Inc. | Tgf-beta inhibitors for use for treating resistant or unresponsive cancer in patients |
CN117721079A (zh) * | 2024-01-26 | 2024-03-19 | 广东壹加再生医学研究院有限公司 | 一种促进nk细胞抗肿瘤活性的培养基及培养方法 |
Family Cites Families (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
JPS6147500A (ja) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
DE768377T1 (de) | 1988-09-02 | 1998-01-02 | Dyax Corp | Herstellung und Auswahl von Rekombinantproteinen mit verschiedenen Bindestellen |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
DK0585287T3 (da) | 1990-07-10 | 2000-04-17 | Cambridge Antibody Tech | Fremgangsmåde til fremstilling af specifikke bindingsparelementer |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
ATE164395T1 (de) | 1990-12-03 | 1998-04-15 | Genentech Inc | Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften |
JP4146512B2 (ja) | 1991-03-01 | 2008-09-10 | ダイアックス コープ. | 小型タンパク質 |
PT100379B (pt) | 1991-04-10 | 1999-01-29 | Scripps Research Inst | Bibliotecas de receptores heterodimericos usando fagomideos |
DE4122599C2 (de) | 1991-07-08 | 1993-11-11 | Deutsches Krebsforsch | Phagemid zum Screenen von Antikörpern |
US5786464C1 (en) | 1994-09-19 | 2012-04-24 | Gen Hospital Corp | Overexpression of mammalian and viral proteins |
EP0889964A1 (en) | 1996-03-28 | 1999-01-13 | The Johns Hopkins University | Soluble divalent and multivalent heterodimeric analogs of proteins |
US6114148C1 (en) | 1996-09-20 | 2012-05-01 | Gen Hospital Corp | High level expression of proteins |
US6914128B1 (en) | 1999-03-25 | 2005-07-05 | Abbott Gmbh & Co. Kg | Human antibodies that bind human IL-12 and methods for producing |
US6492497B1 (en) | 1999-04-30 | 2002-12-10 | Cambridge Antibody Technology Limited | Specific binding members for TGFbeta1 |
US7491516B2 (en) | 2000-06-29 | 2009-02-17 | Abbott Laboratories | Dual specificity antibodies and methods of making and using |
GB0230202D0 (en) * | 2002-12-27 | 2003-02-05 | Domantis Ltd | Ligand |
AR045563A1 (es) * | 2003-09-10 | 2005-11-02 | Warner Lambert Co | Anticuerpos dirigidos a m-csf |
SI1850873T1 (sl) | 2005-02-08 | 2019-05-31 | Genzyme Corporation | Protitelesa proti TGFBETA |
WO2008118356A2 (en) * | 2007-03-22 | 2008-10-02 | Biogen Idec Ma Inc. | Binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind cd154 and uses thereof |
PE20091163A1 (es) | 2007-11-01 | 2009-08-09 | Wyeth Corp | Anticuerpos para gdf8 |
US20100260668A1 (en) | 2008-04-29 | 2010-10-14 | Abbott Laboratories | Dual Variable Domain Immunoglobulins and Uses Thereof |
NZ589436A (en) | 2008-06-03 | 2012-12-21 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
WO2011102483A1 (ja) * | 2010-02-19 | 2011-08-25 | 独立行政法人理化学研究所 | ヒトTGF-βのLAPに結合する抗体 |
AR081556A1 (es) | 2010-06-03 | 2012-10-03 | Glaxo Group Ltd | Proteinas de union al antigeno humanizadas |
RU2015134562A (ru) * | 2011-02-08 | 2018-12-24 | Эббви Инк. | Лечение остеоартрита и боли |
DK2714735T3 (da) * | 2011-06-03 | 2021-10-18 | Xoma Technology Ltd | Antistoffer, der er specifikke for TGF-beta |
US20140286959A1 (en) * | 2011-11-08 | 2014-09-25 | Pfizer Inc. | Methods of Treating Inflammatory Disorders Using Anti-M-CSF Antibodies |
US8871209B2 (en) | 2011-11-14 | 2014-10-28 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for increasing muscle mass and muscle strength by specifically antagonizing GDF8 and or Activin A |
DK2822592T3 (en) * | 2012-03-08 | 2018-10-15 | Ludwig Institute For Cancer Res Limited | TGF-1-SPECIFIC ANTIBODIES AND PROCEDURES AND APPLICATIONS THEREOF |
JP2016521283A (ja) * | 2013-05-06 | 2016-07-21 | スカラー ロック インコーポレイテッドScholar Rock,Inc. | 成長因子モジュレーションのための組成物および方法 |
WO2015171691A2 (en) * | 2014-05-06 | 2015-11-12 | Scholar Rock, Inc. | Compositions and methods for growth factor modulation |
CA3055555A1 (en) | 2016-03-11 | 2017-09-14 | Scholar Rock, Inc. | Tgf.beta.1-binding immunoglobulins and use thereof |
EP3551658A1 (en) * | 2017-01-06 | 2019-10-16 | Scholar Rock, Inc. | Isoform-specific, context-permissive tgf 1 inhibitors and use thereof |
-
2018
- 2018-01-05 EP EP18705030.7A patent/EP3551658A1/en active Pending
- 2018-01-05 PE PE2019001372A patent/PE20191661A1/es unknown
- 2018-01-05 KR KR1020247030136A patent/KR20240137126A/ko unknown
- 2018-01-05 US US15/863,564 patent/US20180207267A1/en not_active Abandoned
- 2018-01-05 JP JP2019536919A patent/JP7157744B2/ja active Active
- 2018-01-05 BR BR112019013908A patent/BR112019013908A2/pt unknown
- 2018-01-05 CA CA3049005A patent/CA3049005A1/en active Pending
- 2018-01-05 CN CN202310792211.2A patent/CN117398457A/zh active Pending
- 2018-01-05 WO PCT/US2018/012601 patent/WO2018129329A1/en unknown
- 2018-01-05 MX MX2019008197A patent/MX2019008197A/es unknown
- 2018-01-05 KR KR1020197022663A patent/KR20190098255A/ko active Application Filing
- 2018-01-05 AU AU2018205231A patent/AU2018205231A1/en active Pending
- 2018-01-05 CN CN201880015969.2A patent/CN110382530A/zh active Pending
- 2018-01-05 CR CR20190350A patent/CR20190350A/es unknown
-
2019
- 2019-03-22 US US16/361,486 patent/US20190209682A1/en not_active Abandoned
- 2019-07-02 IL IL267790A patent/IL267790A/en unknown
- 2019-07-03 PH PH12019501575A patent/PH12019501575A1/en unknown
- 2019-07-05 DO DO2019000180A patent/DOP2019000180A/es unknown
- 2019-07-05 CL CL2019001874A patent/CL2019001874A1/es unknown
- 2019-07-08 CO CONC2019/0007298A patent/CO2019007298A2/es unknown
-
2022
- 2022-10-07 JP JP2022162088A patent/JP2022188226A/ja active Pending
-
2023
- 2023-07-11 IL IL304416A patent/IL304416A/en unknown
- 2023-08-01 US US18/363,435 patent/US20240016928A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
IL304416A (en) | 2023-09-01 |
PE20191661A1 (es) | 2019-11-11 |
US20180207267A1 (en) | 2018-07-26 |
CL2019001874A1 (es) | 2019-12-06 |
CN110382530A (zh) | 2019-10-25 |
US20190209682A1 (en) | 2019-07-11 |
PH12019501575A1 (en) | 2019-11-04 |
DOP2019000180A (es) | 2019-09-15 |
MX2019008197A (es) | 2019-09-11 |
EP3551658A1 (en) | 2019-10-16 |
KR20190098255A (ko) | 2019-08-21 |
AU2018205231A1 (en) | 2019-07-18 |
JP2020503362A (ja) | 2020-01-30 |
CR20190350A (es) | 2019-11-15 |
US20240016928A1 (en) | 2024-01-18 |
JP7157744B2 (ja) | 2022-10-20 |
CN117398457A (zh) | 2024-01-16 |
KR20240137126A (ko) | 2024-09-19 |
BR112019013908A2 (pt) | 2020-02-04 |
CA3049005A1 (en) | 2018-07-12 |
JP2022188226A (ja) | 2022-12-20 |
WO2018129329A1 (en) | 2018-07-12 |
IL267790A (en) | 2019-09-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2019007298A2 (es) | Inhibidores de tgfβ1 isoforma-específicos contexto-permisivos y uso de los mismos | |
CO2019012353A2 (es) | Formulaciones de anticuerpos anti-lag3 y coformulaciones de anticuerpos anti-lag3 y anticuerpos anti-pd-1 | |
CO2021001912A2 (es) | Composiciones anti-cd112r y métodos | |
CL2018002012A1 (es) | Derivados de maitansinoide, conjugados de los mismos y métodos de uso. | |
BR112019005908A2 (pt) | uso de combinação de anticorpo anti-pd-1 e inibidor de vegfr na preparação de fármaco para tratamento de cânceres | |
CL2016002027A1 (es) | Ciclopropilamina como inhibidor de la lsd1 | |
ECSP15026557A (es) | Compuestos y sus métodos de empleo | |
CO2017001994A2 (es) | Compuestos activos hacia bromodominios | |
CY1123290T1 (el) | Ενωσεις και μεθοδοι χρησης | |
CL2015002472A1 (es) | Como inhibidores de mutant idh-yl-oxazolidin-2-onas 3-pirimidin-4. | |
CL2018002698A1 (es) | Tratamiento de enfermedades inflamatorias con inhibidores de actividad c5a | |
CL2016000807A1 (es) | Amino heteroarilo benzamidas como inhibidores de quinasa. | |
CL2016001609A1 (es) | Composiciones farmacéuticas que comprenden azd9291. | |
CL2020003202A1 (es) | Piridinil y pirazinil-(aza)indolsulfonamidas | |
BR112015023760A2 (pt) | compostos e composições terapêuticas | |
BR112018000254A2 (pt) | inibidores de pde9 com cadeia principal de imidazotriazinona e cadeia principal de imidazopirazinona para o tratamento de doenças periféricas | |
CL2020003249A1 (es) | Antagonista gremlin-1 para la prevención y tratamiento del cáncer | |
BR112016017112A2 (pt) | Composições de apilimod e métodos de uso das mesmas | |
EA202191557A1 (ru) | Комбинированная терапия радиоиммуноконъюгатами и ингибиторами репарации повреждений днк | |
CL2019003670A1 (es) | Composición que comprende manosa oligosacárido y proceso para realizarla y uso de esta. | |
CL2018003417A1 (es) | Nuevos compuestos. | |
CO2020001107A2 (es) | Moduladores terapéuticos del modo inverso de la atp sintasa | |
CL2020000056A1 (es) | Nuevos derivados de xantina sustituidos. | |
UY38352A (es) | Inhibidores de integrina alfavbeta6 | |
CL2022000522A1 (es) | Lurbinectedina en el tratamiento del mesotelioma maligno. |